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Abstract: OBJECTIVE To use the concept of benchmarking to establish robust and standardized out-
come references after pancreatico-duodenectomy (PD). BACKGROUND Best achievable results after
PD are unknown. Consequently, outcome comparisons among different cohorts, centers or with novel
surgical techniques remain speculative. METHODS This multicenter study analyzes consecutive patients
(2012-2015) undergoing PD in 23 international expert centers in pancreas surgery. Outcomes in pa-
tients without significant comorbidities and major vascular resection (benchmark cases) were analyzed to
establish 20 outcome benchmarks for PD. These benchmarks were tested in a cohort with a poorer preop-
erative physical status (ASA class ฀3) and a cohort treated by minimally invasive approaches. RESULTS
Two thousand three hundred seventy-five (38%) low-risk cases out of a total of 6186 PDs were analyzed,
disclosing low in-hospital mortality (฀1.6%) but high morbidity, with a 73% benchmark morbidity rate
cumulated within 6 months following surgery. Benchmark cutoffs for pancreatic fistulas (B-C), severe
complications (฀ grade 3), and failure-to-rescue rate were 19%, 30%, and 9%, respectively. The ASA ฀3
cohort showed comparable morbidity but a higher in hospital-mortality (3% vs 1.6%) and failure-to-rescue
rate (16% vs 9%) than the benchmarks. The proportion of benchmark cases performed varied greatly
across centers and continents for both open (9%-93%) and minimally invasive (11%-62%) PD. Centers
operating mostly on complex PD cases disclosed better results than those with a majority of low-risk
cases. CONCLUSION The proposed outcome benchmarks for PD, established in a large-scale interna-
tional patient cohort and tested in 2 different cohorts, may allow for meaningful comparisons between
different patient cohorts, centers, countries, and surgical techniques.
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Objective: To use the concept of benchmarking to establish robust and
standardized outcome references after pancreatico-duodenectomy (PD).
Background: Best achievable results after PD are unknown. Consequently,
outcome comparisons among different cohorts, centers or with novel surgical
techniques remain speculative.
Methods: This multicenter study analyzes consecutive patients (2012–2015)
undergoing PD in 23 international expert centers in pancreas surgery. Out-
comes in patients without significant comorbidities and major vascular
resection (benchmark cases) were analyzed to establish 20 outcome
benchmarks for PD. These benchmarks were tested in a cohort with a poorer
preoperative physical status (ASA class3) and a cohort treated byminimally
invasive approaches.
Results: Two thousand three hundred seventy-five (38%) low-risk cases out
of a total of 6186 PDs were analyzed, disclosing low in-hospital mortality
(1.6%) but high morbidity, with a 73% benchmark morbidity rate cumulated
within 6 months following surgery. Benchmark cutoffs for pancreatic fistulas
(B-C), severe complications ( grade 3), and failure-to-rescue rate were 19%,
30%, and 9%, respectively. The ASA 3 cohort showed comparable mor-
bidity but a higher in hospital-mortality (3% vs 1.6%) and failure-to-rescue
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rate (16% vs 9%) than the benchmarks. The proportion of benchmark cases
performed varied greatly across centers and continents for both open (9%–
93%) and minimally invasive (11%–62%) PD. Centers operating mostly on
complex PD cases disclosed better results than those with a majority of low-
risk cases.
Conclusion: The proposed outcome benchmarks for PD, established in a
large-scale international patient cohort and tested in 2 different cohorts, may
allow for meaningful comparisons between different patient cohorts, centers,
countries, and surgical techniques.
Keywords: benchmarks, minimally invasive surgery, outcomes, pancreatic
surgery, pancreatoduodenectomy, quality of care, surgical complications
(Ann Surg 2019;270:211–218)
P ancreatico-duodenectomy (PD) is frequently performed for anumber of diseases, particularly in patients with pancreatic
adenocarcinoma.1 This procedure is, however, still associated with
significant perioperative mortality and high morbidity, which
strongly impacts patient’s quality of life and costs.2–7 The major
shortcoming of quality comparisons in complex surgery is the
absence of standardized benchmarks for outcome indicators in a
well-defined patient population, which may serve as reference
values.8 For instance, novel minimally invasive laparoscopic or
robotic approaches are promoted by many surgeons claiming supe-
riority, although genuine reference data in the classical open proce-
dure are still lacking.
The concept of benchmarking is a widely used tool for quality
improvement in the manufacturing industry and economy, but its use
in medicine has been more versatile and imprecise.9 The novel idea
of applying the benchmark concept to surgery is to assess best
achievable results in a well-defined low-risk patient cohort to estab-
lish meaningful reference values for comparisons, for example
among centers or over time, or to evaluate the implementation of
novel surgical techniques.10 Recent studies in the field of surgery
have applied this methodology to set reference figures in liver
resection, transplantation, and esophagectomy.11–13
Outcome indicators should no longer be based exclusively on
mortality, but rather cover other relevant endpoints for the patients
and health care system. Consistent with the concept of value-based
medicine, special emphasis should be put on cumulative morbidity
extending well after index-hospital discharge.14
Consequently, this study aims at establishing a variety of
clinically relevant outcome benchmark values for PD from a low-
risk cohort treated at high volume centers covering 3 continents. As
an example of utility, similar data were collected from a few expert
centers performing laparoscopic and robotic PD, and compared with
the established benchmark values for open PD. The proposed stan-
dardized benchmark methodology for outcome analysis and report-
ing might be an important step to improve quality and validate novel
strategies for complex surgical procedures.
METHODS
Study Design
Establishing benchmarks in surgery followed a standardized
methodology, previously applied and reported for major hepatec-
tomy, liver transplantation, and esophagectomy.11–13 First, a large
patient cohort from international expert centers was selected to
define best practice. Only patients with a low preoperative risk
profile were selected, using well-defined inclusion criteria
(Table 1). Second, relevant outcome indicators for quality of surgical
care were assessed in this low risk population. For each outcome
indicator, a numeric benchmark cutoff was calculated indicating the
‘‘best achievable’’ results. These benchmark cutoffs were applied to
identify clinically relevant performance gaps in different patient
cohorts, internal, or external to the expert centers, which may then
be addressed by specific quality improvement measures. This pro-
cess is commonly referred to as benchmarking.
Patient and Hospital Selection
Hospitals in Asia, Europe, and America were screened to
identify centers performing high-volume pancreatic surgery ( 50
complex pancreas interventions per year).4,15,16 Only the largest
programs having previously published their results and holding a
prospective database were contacted to participate to the study. The
final collaborative consortium included 23 centers: 13 from Europe
(Amsterdam, Barcelona, Birmingham, Lisbon, Lyon, Mainz, Paris,
Pisa, Rennes, Rotterdam, Stockholm, Verona, and Zurich), 6 from
USA (Atlanta, Baltimore, Boston, Denver, New York, and Phila-
delphia), and 4 from Asia (Tokyo, Chiba, and 2 from Seoul).
From the 23 included centers, we selected only patients
undergoing open PD for malignant or benign pancreatic diseases
localized in the pancreatic head, without distant metastases or
involvement of the arterial axis. To further narrow the selection to
patients with a low-preoperative risk-profile, comorbidities proven to
negatively impact the postoperative course, for example American
Society of Anesthesiologists (ASA) classification 3, body mass
index>35 kg/m2, and anticoagulation drug therapy, were considered
as exclusion criteria.17–24 (Table 1)
Patient and outcome data were centralized in a secure and
anonymized online data management system provided by the Uni-
versity Hospital of Zurich (https://www.whipplebenchmarks.org).
The data were audited and checked for completeness by 3 local
TABLE 1. Selection Criteria for Low-risk Patients Included in
the Benchmark Analysis
Inclusion criteria
Age  18 yrs
Open PD for resectable malignant and benign pancreatic disease
Exclusion criteria-surgical
Extended or total pancreatico-duodenectomy
Resection of the mesenteric artery/celiac trunk
Macroscopic positive margins (R2) (16)
Extrapancreatic metastases (non-nodal) (16)
Previous major abdominal surgery (ie, bariatric surgery, liver surgery,
splenectomy)
Minimally invasive procedures (laparoscopic or robotic)
Exclusion criteria-comorbidities
American Society of Anesthesiologists (ASA) classification 3 (16)
Body mass index  35 kg/m2 (15)
Cardiac disease defined as (17,18):
Congestive heart failure (CHF) onset or exacerbation in 30 d prior to
surgery
History of angina pectoris within 1 month of surgery
Myocardial infarct within 6 months prior to surgery
History of percutaneous coronary intervention or cardiac surgery
Atrial fibrillation
Chronic renal failure MDRD  Stage 3 (19)
GRF<60 mL/min per 1.73 m2 or Serum creatinine > 1.8 mg/dL or
160mmol/L
Chronic obstructive pulmonary disease with FEV1<80% (22)
Exclusion criteria-medication
Use of anticoagulants (20,21)
Nonvitamin K antagonist oral anticoagulants (NOACs)
Vitamin K antagonist
Clopidogrel
2 oral antidiabetic drugs or insulin (16)
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investigators (P.S.V., X.M., and C.T.). Only patients with a minimal
follow-up of 1 year were included in the study.
Ethical approval from the institutional ethical board of the
University Hospital of Zurich (KEK 2017-01638) and from each
respective center was obtained before analysis of the data.
Outcome Indicators
Twenty clinically relevant intra - and postoperative outcome
indicators were selected to establish serial outcome benchmark
cutoffs at discharge, 3, 6, and 12 months. In detail, perioperative
parameters, which have been previously shown to be associated with
surgical performance, namely duration of the intervention, percent-
age of intraoperative blood transfusions, and hospital stay, were
included.25–28 Special emphasis was put on postoperative compli-
cations, as they are recognized to reflect surgical outcomes more
comprehensively than mortality alone.29,30 To accurately reflect
morbidity, each postoperative complication was assessed for every
single patient during the postoperative course. Additionally, the
severity of the complications were graded using the Clavien–Dindo
classification, which defines the severity of the complication by the
treatment intervention required.31Of note, the index-complication of
PD, postoperative pancreatic fistulas (POPF), was also graded using
the updated International Study Group on Pancreatic Fistula classi-
fication.32 To investigate the proportion of fatalities following a
postoperative complication, we calculated the failure-to-rescue rate
according to a previously published methodology: the number of
deaths in patients with a complications graded> II (numerator) to the
total number of patients with a complication graded > II (denomi-
nator).33
The comprehensive complication index (CCI1) was used to
cover the total number of complications by severity for every
single patient.34,35 The CCI1 adds each complications graded by
the Clavien–Dindo system into a continuous numeric score ranging
from 0 (uneventful course) to 100 points (death). This index has been
shown to enable a quantification of the cumulative morbidity burden
for a single patient over a certain period of time, extending for
example to 1 year.12,13
For the subgroup of patients with pancreatic adenocarcinoma,
validated oncological quality indicators including resection margins,
number of lymph nodes resected, and disease-free survival were
additionally assessed.18,36,37
Definition and Applications of Benchmarks
The benchmark cutoff for a given outcome indicator is calcu-
lated as the 75th percentile of the median value for each center.10 To
account for variability across centers, the medians as well as the
ranges are also depicted.
To illustrate the ability of the established benchmarks to
identify small differences in outcomes, we analyzed outcomes in
a cohort of patients from the same centers and differing from the
benchmark cohort by a poorer preoperative physical status, defined
by an ASA class 3.38
To further illustrate the utility of the benchmark concept, we
tested the benchmark values in cohorts of patients gathered from 3
recognized institutions performing minimal-invasive PD using either
a robotic or laparoscopic approach.39–42 Of note, apart from the
minimally invasive approach, this cohort fulfilled the same selection
criteria as the benchmark cohort for open PD (Table 1).
Center Specific Risk Profile
To inquire howmany high-risk cases a center is performing, we
stratified the 23 centers according to their respective proportion of
benchmark versus nonbenchmark cases and analyzed the relation of
this center specific risk profilewith outcomes in the benchmark cohort.
Statistical Analysis
Statistical analysis was performed using the SPSS statistical
software package (SPSS, version 20, IBM, Armonk, NY), Stat 10.1
(version 19), and Graph Pad Prism7. The Kolmogorov–Smirnov test
was used to determine the distribution of the variables. Categorical
variables were compared using the Fischer exact or the Pearson chi-
square tests, where appropriate. The Student t test was used to make
pairwise comparisons of normally distributed parameters and the
Mann–Whitney U test was used for nonparametric data. Pearson
correlation was performed to compute correlation coefficients
between measured variables. Tests were considered statistically
significant at a 2-sided P value of < 0.05.
RESULTS
From the 23 high-volume international centers performing a
total 6186 PD cases during the 3-year study period, 2375 (38%)
low-risk patients constituted the cohort for the benchmark analysis.
The median patient follow-up after surgery was 23 months (IQR:
13–34 mo). In nearly half (n ¼ 1091, 46%) of the cases, the
indication for PD was adenocarcinoma, followed by ampullary
carcinoma (n ¼ 327, 13.8%) and cholangiocarcinoma (n ¼ 266,
11.2%). Of all the patients with an oncological indication for PD,
the majority (55%) presented a stage T3 disease. For patients with
adenocarcinoma (n ¼ 1091), 14% received neo-adjuvant therapy
and 65% adjuvant treatment. Benign diseases such as Intraductal
Papillary Mucinous Neoplasia (n ¼ 197, 8.3%), chronic pancreati-
tis (n ¼ 47, 2%), and other cystic lesions (n ¼ 38, 8.3%) were less
frequent. The texture of the pancreatic gland was reported as soft in
42.1% (n ¼ 999) and hard in 34.7% (n ¼ 824) of the cases. No
information on texture was available in 23% of the cases (n¼ 551).
Of note, among the 1682 patients with documented pancreatic duct
measurement, more than half (62.7%, n ¼ 1490) presented a duct
size > 3mm. Detailed baseline characteristics can be found in
Supplementary Digital Content Table 1, http://links.lww.com/
SLA/B583.
Outcome Benchmarks
Twenty benchmark cutoffs, derived from the 75th percentile
of the medians for each outcome indicator per center, were estab-
lished from this low-risk patient cohort (Table 2). The 6-months
time point was chosen as follow-up to assess these outcome
indicators, since the overall median cumulative patient morbidity
expressed by the CCI1 increased 2.4 from index-hospital dis-
charge (CCI1: 8.6) until 6 months after surgery (CCI1: 20.9) for
the entire benchmark cohort and did not increase significantly
thereafter. (Supplementary Digital Content Figure S1, http://links.
lww.com/SLA/B583).
In-hospital mortality rates and overall 6-months morbidity
were 1.6% and  73%, respectively with a readmission rate of
21%. The benchmark cutoff for postoperative clinically relevant
pancreatic fistula rate (grade B–C) was  19%. The benchmark rate
for failure-to-rescue was 9% with the most frequent complication-
related death being postoperative bleeding (0.3%).
Outcome Comparisons
The applicability of the benchmark values for outcome com-
parisons was tested in 2 independent cohorts of patients (Table 3).
First, we identified 931 patients, who underwent PD in
the same 23 centers only differing from benchmark cases by a
poorer preoperative physical status (ASA class 3). In this cohort,
morbidity was within the benchmark while in-hospital mortality and
failure-to-rescue rate were outside the established benchmark values
(16% vs 9%).
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Second, in a cohort of 224 patients undergoing minimally
invasive PD in 3 centers, 79 patients (35%) fulfilled the selection
criteria for benchmark (low-risk) cases. During the study period, the
proportion of benchmark cases was higher in one of the centers
performing robotic PD (62%) than in the other two minimal-invasive
PD (11% and 16%). In benchmark patients undergoing minimally
invasive PD, operation duration and readmission rates exceeded the
benchmark cutoffs in 2 of the 3 centers, while other more specific
morbidity indicators, for example POPF rates, showed a large
variation (0%–23%).
TABLE 2. Twenty Outcome Benchmarks After PD in 2375 Low-risk Cases From Twenty-three International High-volume
Centers
Median Across the 23 Centers (Range) Benchmark Cutoff
Operating duration 6.1 h (3.4–8.6) 7.5 h
Blood transfusions 13% (2–36.4) 23%
Hospital stay 12 d (6–31) 15 d
Postoperative 6-mos morbidityy
Patients with at least 1 complication (graded as Clavien–Dindo) 65.3% (43.5–89.6) 73%
Patients with a complication Grades I–II 53% (30.6–86.5) 62%
Patients with a complication Grade  III 19% (4.4–52.3) 30%
Patients with a complication Grade IV 2% (0–14) 5%
CCI1 20.9 (0–33.5) 20.9
Pancreatic fistula rate (ISGPF classification B–C) 10% (0–35.4) 19%
Grade B 8% (0–35.4) 15%
Grade C 2% (0–12) 5%
Biochemical leak 8% (1.3–22.7) 13%
Severe postoperative bleeding ( III) 4% (0–14) 7%
In-hospital mortality 0% (0–4) 1.6%
Failure-to-rescue rate 0% (0–25) 9%
Readmission rate 16% (1.6–29.1) 21%
Oncological outcomes in patients with PADC (n ¼ 1091)
R1 rate 27% (2.3–67) 39%
Number of lymph nodes resected 19 (14–43) 16
1-yr DFS survival (actual) 42% (22.6–100) 53%
3-yrs DFS survival (actuarial) 0% (0–15.4) 9%
CCI
1
ranges from 0 (no complication) to 100 (death).
yThe values at discharge, 3 mo and 12 mo are listed in the supplementary material (Table S4, http://links.lww.com/SLA/B583).
TABLE 3. Examples of Benchmark Comparisons in 4 Different Cohorts: One Cohort With a Poorer Preoperative Physical Status














(75th Percentile of Medians
From 23 Centers)
% Benchmark cases 8/37 (22%) 8/51 (16%) 62/100 (62%) –
Operating duration 6 h 7.6 hy n.a. 8.3 hy 7.5 h
Blood transfusions 14.7% 12.5% n.a. 4.8% 23%
Hospital stay 10 d 4.5 d 6.5 d 16 d 15 d
6 mo postoperative morbidity
Patients with at least 1 complication (graded as Clavien–Dindo) 60% 38% 63% 68% 73%
Patients with a complication Grades I–II 50% 38% 12.5% 62% 62%
Patients with a complication Grade  III 19% 13% 50%y 13% 30%
Patients with a complication Grade IV 4% 0% 0% 0 5%
CCI1 20.9 4 17.5 20.9 20.9
Pancreatic fistula rate (ISGPF Classification B–C) 10% 13% 0% 23%y 19%
Grade B 7% 13% 0% 21%y 15%
Grade C 3% 0% 0% 2% 5%
Biochemical leak 5% 13% 0% 8% 13%
Severe postoperative Bleeding ( III) 3% 0% 0% 10%y 7%
In-hospital mortality 3%y 0% 0% 3%y 1.6%
Failure-to-rescue 16%y 0% 0% 25%y 9%
1-yr readmission rate 20% 25%y 50%y 7% 21%
Oncological outcomes in patients with PADC
R1 rate 21% 0 n.a. n.a. 39%
Total of harvested Lymph nodes (number) 22 32 13y 35 16
1-yr DFS survival (actual) 41%y n.a. n.a. n.a. 53%
3-yrs DFS survival (actuarial) 2.5%y n.a. n.a. n.a. 9%
CCI
1
ranges from 0 (no complication) to 100 (death).
yValues are outside of the benchmark.
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Center-specific Risk Profile
The proportion of benchmark cases respective to the total PD
volume greatly varied among centers, ranging from 9% to 93%
(Fig. 1). This center-specific case-mix, however, did not correlate
with the center-volume (r¼0.14, P ¼ 0.52) (Fig. 2). We observed
that higher proportion of benchmark cases correlated with higher
fistula rates in the benchmark cases (r ¼ 0.53; P ¼ 0.009). For
example, center #23 performed 9% benchmark cases (n ¼ 79 out of
total 881) with a postoperative pancreatic fistula rate (grades B–C) of
6% (n ¼ 5). In contrast, center #13 performed mostly benchmark
cases (93%, n ¼ 218 out of a total of 235 patients) with a postopera-
tive fistula rate (grades B–C) of 32% (n ¼ 70) (Fig. 2). A similar
correlation was observed for overall morbidity rates and proportion
of benchmark cases (r ¼ 0.39, P ¼ 0.06, Figure S2, http://link-
s.lww.com/SLA/B583). In addition, the centers performing<50% of
benchmark cases disclosed a 2 lower failure-to-rescue rate (3.6%
vs 7.0%, P ¼ 0.138).
The same correlation between proportion of benchmark cases
and outcomes was also observed in the higher risk cohort for example
for POPF rates (r ¼ 0.45, P ¼ 0.04, Figure S3, http://links.lww.com/
SLA/B583). When analyzing the 3 minimally invasive PD sub-
groups, the 2 centers performing the smallest proportion of bench-
mark cases displayed the lowest fistula rate (grades B–C) and in-
hospital mortality (Table 3).
In addition, this center-specific risk profiles – based on the
proportion of benchmark versus non benchmark cases – followed a
geographical distribution (Fig. 3). Centers in the US operated on a
significantly higher proportion of cases outside of the benchmark
criteria (82%), when compared with European (56%) and Asian
(32%) centers (P<0.001). In line with the correlation between the
risk profile and outcomes, the overall postoperative fistula rate in the
benchmark cases was lower in the US centers (6.5%), when com-
pared with European and Asian centers (17% and 20%, P<0.001)
(Fig. 3). Of note, factors influencing the occurrence of POPF, for
example soft pancreatic texture or the use of chemotherapy prior to
surgery in patients with pancreas adenocarcinoma, had similar
distributions across the 3 continents.
DISCUSSION
This study provides 20 benchmark values for surgical and
oncological outcomes after PD showing low in-hospital mortality,
but high morbidity rates increasing up to 6 months after surgery. The
study also offers benchmarks for oncological indicators such a 1-year
disease-free survival (53%) or minimal number of harvested lymph
nodes (16). The benchmark values were tested in 2 different
cohorts of patients, 1 in patients from the same centers with a poorer
preoperative physical status (ASA class 3) and another series of
cases undergoing minimally invasive PD, which enabled us to detect
and quantify specific outcome parameters beyond the benchmark
values. This novel concept of benchmarks for complex surgical
procedures may serve as a robust methodology to improve outcome
comparisons among different patient groups, centers, and countries,
FIGURE 1. Large variations in the proportion of benchmark cases performed across the 23 centers.
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or even to test whether single cases lie inside or outside benchmark
values. Additionally, the results showed a correlation between the
proportion of difficult cases performed in a center and center-specific
outcomes, independently of the total case volume.
In an effort to apply the benchmark concept for pancreas
surgery, this study followed a standardized and previously reported
methodology by focusing on a low-risk patient population, called
benchmark cases, from 23 international high-volume centers.10 From
this large-scale patient cohort, reference values for 20 outcome
parameters, that is, benchmark values or cutoffs, were established
for indicators reflecting postoperative mortality, morbidity, and other
clinically relevant endpoints like hospital stay and oncological
indicators.
The results of the study show that even in benchmark cases
undergoing PD, postoperative morbidity doubled between discharge
and 6 months postoperatively as assessed by the overall cumulative
morbidity index, CCI1. This finding is also well reflected by a
benchmark readmission value of 21%. Based on this observation,
reliable reports on outcomes in patients undergoing PD must cover at
least the first 6 postoperative months. Coupled to a recent study
published in this journal showing a close correlation between CCI1
and costs, we would expect that the financial burden for PD extends
up to 6 months after surgery, which should be taken into account for
proper reimbursement.43
To illustrate the applicability of the established benchmark
cutoffs for outcome comparisons with other cohorts undergoing
PD, we first analyzed nearly thousand patients, only differing
from the benchmark cases by a poorer preoperative physical
status (ASA class 3). In this cohort, morbidity rates increased
but stayed within the benchmark cutoffs. However, the failure-to-
rescue rate showed a 2-fold increase comparedwith the benchmark,
which lead to an in-hospital mortality outside the benchmark
cutoffs.33 Interestingly, similar outcome differences in patients
differing by ASA class have been observed in previous studies.38,44
We believe that this example nicely shows that the established
benchmarks enable us to disclose novel insights, by evaluating
selective outcome indicators in patients differing only by baseline
characteristics.
FIGURE 3. Geographical distribution of the single center proportion of benchmark cases and associated postoperative fistula rates
(Expressed as median and interquartile range).
FIGURE 2. Relation of the proportion of benchmark cases with the total center volume and postoperative fistula rates (Grades
B–C). Each point in the graph represents 1 of the 23 centers included in the study.
Sánchez-Velázquez et al Annals of Surgery  Volume 270, Number 2, August 2019
216 | www.annalsofsurgery.com  2019 Wolters Kluwer Health, Inc. All rights reserved.
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
As a second illustration, we assessed outcomes after mini-
mally invasive (laparoscopic or robotic) PD in benchmark patients
treated at 3 centers with expertise in such approaches. Here, while the
majority of outcome indicators were within the cutoffs, comparisons
with the benchmarks allowed us to identify center-specific outcomes
outside of the cutoffs, for example operation duration and
readmission rates.
These examples show how benchmarks can be used for
outcome comparisons within and between single center cohorts,
and identify center-specific differences.
An unexpected finding of this study was the large variation in
the proportion of benchmark cases across the 23 high-volume
centers, all performing over 50 complex pancreatic procedures per
year. We observed that centers operating on a high proportion of
benchmark cases had inferior outcomes compared with centers
performing more difficult cases, independently of the overall vol-
ume. The strongest correlation was observed for clinically relevant
pancreatic fistulas (B and C). In other words, centers exposed to
difficult cases had better results in their benchmark cases. A possible
explanation for this observation is that a high proportion of complex
cases enhance surgeon’s skills, which may in turn improve manage-
ment of complications through an experienced multidisciplinary
team, and thereby preventing failure-to-rescue.45 Indeed, in the
current study the centers having less experience with difficult PD
cases disclosed a 2 higher failure-to-rescue rates. We also noted a
geographical distribution in the rate of complications and fistulas
with superior results in the USA. This finding could be explained by
the different risk profile among the regions, although of course other
factors cannot be excluded.
A similar variation in the proportion of benchmark cases was
observed among the 3 centers performing minimally invasive PD,
which likewise may explain differences in outcomes. The center with
the largest case volume disclosed the greatest proportion of bench-
mark cases, and also more indicators outside the benchmark values,
than the other 2 centers with a smaller case load but more ‘‘high
risk’’ cases.
A new finding of this study is therefore that center-risk profile
may add to the current volume-based surgical assessment and
centralization strategies.4,15,16,45–47 Case volume alone is an insuffi-
cient proxy for performance, if not coupled with information on the
proportion of benchmark cases. The results of this study suggest that
to gain a sufficient expertise in PD with better results, centers must
accept and perform difficult cases irrespective of their caseload. The
main message of this study, however, remains that assessment of
centers or perhaps individual surgeons or new minimally invasive
approaches should be based on the well-defined benchmark popula-
tion to measure outcomes in a standardized patient population
without the need of cumbersome risk adjustment. An application
at the level of individual centers might be to use the benchmark
cutoffs to identify cases to be presented at morbidity-mortality
conferences. We have implemented this policy in Zurich,
Switzerland to review all the specific steps within the care process
in patients with a CCI1 outside of the benchmark. Learning from
these cases could reduce the failure-to-rescue rate, which is known to
be a key factor for improved outcome in specialized centers.33
This study has unavoidable limitations. First, the selection
criteria for the low-risk benchmark patients did not include intra-
operative features such as gland texture, pancreatic duct size, or other
technical variations in performing the surgery. Although these factors
do impact on outcomes, they are rarely available preoperatively, and
thus lack pragmatic values. Therefore, we made the choice to
exclusively focus on readily available and well-defined preoperative
features. Second, while reporting of complications and pancreatic
fistulas was standardized for all centers, oncological indicators such
as resection margins and number of resected lymph nodes were
recorded according to the local protocols. Thus, some variations
related to the difference in definitions and quality of the pathological
examinations at different centers cannot be excluded. Since this study
was not designed to assess outcomes after laparoscopic or robotic
PD, no generalizable conclusions should be drawn from these
comparisons, which serve as an illustration of the utility of bench-
mark values in outcome assessment.
The current study is a first attempt to apply benchmarking in
pancreatic surgery. Further studies should now test these cutoffs in
independent cohorts undergoing PD to validate and broaden
this concept.
In conclusion, this international large-scale study proposes a
novel approach for outcome analysis of PD by proposing benchmark
values for clinically relevant outcome indicators. Individual outcome
parameters from single patients, centers, geographical areas, or after
minimally invasive procedures may be compared with the estab-
lished benchmark values to enable an objective assessment of
performance gaps and learning curves. In addition, center-risk
profiles, based on the proportion of benchmark versus nonbenchmark
cases may provide additional information on center practice and may
reflect outcomes more accurately than center volume alone.
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